Limit this search to....

Multiple Myeloma: Translational and Emerging Therapies
Contributor(s): Anderson, Kenneth C. (Editor), Irene, M. Ghobrial (Editor)
ISBN: 1420045105     ISBN-13: 9781420045109
Publisher: CRC Press
OUR PRICE:   $95.00  
Product Type: Hardcover - Other Formats
Published: October 2007
Qty:
Annotation: Multiple myeloma is the second most prevalent hematological malignancy, with over 55,000 new cases diagnosed each year. This exciting reference, edited by lauded authorities on the topic, stands as the only available reference to assemble, review, and synthesize the latest studies on translational therapies, and clearly explains the impact of molecular pathogenesis, biology, and prognostic factors on the diagnosis, prognosis, and individualization of treatment and the development of novel therapeutic options for patients with myeloma. Moving from the bench to the bedside to the forefront of therapeutic development, this source helps clinicians and researchers effectively deploy therapeutic strategies into clinical practice???reflects trends in the use of agents which target both the tumor cell and its bone marrow microenvironment to overcome resistance to conventional therapies???considers the critical role of the bone marrow microenvironment in the regulation of growth, survival, and homing of multiple myeloma???discusses novel therapies in phase I and phase II trials, focusing specifically on therapeutic options for patients with newly diagnosed or relapsed/refractory multiple myeloma???addresses novel therapies for other plasma cell disorders, and provides the framework for the design of next generation agents and combination therapies???and covers the entire scope of translational work in multiple myeloma, from advances in molecular pathogenesis, to prognostic factors, immunotherapy, and new options for newly diagnosed and relapsed multiple myeloma patients.
Additional Information
BISAC Categories:
- Medical | Hematology
- Medical | Oncology - General
Dewey: 616.994
LCCN: 2007023651
Series: Translational Medicine
Physical Information: 0.87" H x 6.31" W x 9.27" (1.22 lbs) 320 pages
 
Descriptions, Reviews, Etc.
Publisher Description:

Multiple myeloma is the second most prevalent hematological malignancy, with over 55,000 new cases diagnosed each year. This exciting new text, edited by lauded authorities on the topic, stands as the only available reference to assemble, review, and synthesizes the latest studies on translational therapies and clearly explains the impact of molecular pathogenesis, biology, and prognostic factors on the diagnosis, prognosis, and individualization of treatment and the development of novel therapeutic options for patients with myeloma.

Moving from the bench to the bedside to the forefront of therapeutic development, this source:

  • helps clinicians and researchers effectively deploy therapeutic strategies into clinical practice
  • reflects trends in the use of agents which target both the tumor cell and its bone marrow microenvironment to overcome resistance to conventional therapies
  • considers the critical role of the bone marrow microenvironment in the regulation of growth, survival, and homing of multiple myeloma
  • discusses novel therapies in phase I and phase II trials, focusing specifically on therapeutic options for patients with newly diagnosed or relapsed/refractory multiple myeloma
  • addresses novel therapies for other plasma cell disorders, and provides the framework for the design of next generation agents and combination therapies
  • covers the entire scope of translational work in multiple myeloma, from advances in molecular pathogenesis, to prognostic factors, immunotherapy, and new options for newly diagnosed and relapsed multiple myeloma patients